NASDAQ:ALEC Alector Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.73 +0.21 (+2.00%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$10.18▼$10.8750-Day Range$7.65▼$11.4752-Week Range$7.50▼$43.32Volume1.17 million shsAverage Volume729,655 shsMarket Capitalization$894.10 millionP/E RatioN/ADividend YieldN/APrice Target$29.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address ALEC Stock Forecast (MarketRank)Overall MarketRank™2.27 out of 5 starsMedical Sector308th out of 1,418 stocksBiological Products, Except Diagnostic Industry46th out of 216 stocksAnalyst Opinion: 3.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.86, Alector has a forecasted upside of 178.3% from its current price of $10.73.Amount of Analyst CoverageAlector has only been the subject of 1 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesAlector has received 135 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlector has received 80 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlector has received 62.79% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote “Outperform” if you believe ALEC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,542.00 in company stock.Percentage Held by Insiders14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.69% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($1.36) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -25.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -25.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alector (NASDAQ:ALEC)Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Stock News HeadlinesJune 24, 2022 | americanbankingnews.comAlector (NASDAQ:ALEC) Shares Up 7.9%June 16, 2022 | investors.comRoche Stock: Alzheimer's Failures Keep Piling Up - Investor's Business DailyJune 11, 2022 | americanbankingnews.comAlector, Inc. (NASDAQ:ALEC) Receives $31.50 Consensus Target Price from BrokeragesJune 10, 2022 | streetinsider.comAlloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines - StreetInsider.comJune 8, 2022 | finance.yahoo.comAlector to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceJune 1, 2022 | nasdaq.comSize Up SBIO as Biotech Catalysts Emerge - NasdaqMay 30, 2022 | seekingalpha.comMorgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking AlphaMay 28, 2022 | finance.yahoo.comAlector Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Yahoo FinanceMay 24, 2022 | benzinga.comGoldman Sachs Maintains Sell on Alector, Lowers Price Target to $6 - Benzinga - BenzingaMay 9, 2022 | finance.yahoo.comAdimab Announces Promotions of New Chief Executive Officer and President - Yahoo FinanceMay 9, 2022 | businesswire.comAdimab Announces Promotions of New Chief Executive Officer and President - Business WireMay 5, 2022 | finance.yahoo.comAlector Reports First Quarter 2022 Financial Results and Provides Business Update - Yahoo FinanceMay 5, 2022 | finance.yahoo.comAlector Reports First Quarter 2022 Financial Results and Provides Business UpdateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees208Year FoundedN/ACompany Calendar Last Earnings11/04/2021Today6/24/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$29.86 High Stock Price Forecast$57.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+178.3%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.420010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36.33 million Net Margins-12.65% Pretax Margin-12.32% Return on Equity-10.57% Return on Assets-3.81% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual Sales$207.09 million Price / Sales4.32 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book2.90Miscellaneous Outstanding Shares83,327,000Free Float71,661,000Market Cap$894.10 million OptionableNot Optionable Beta1.37 Alector Frequently Asked Questions Should I buy or sell Alector stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Alector stock. View analyst ratings for Alector or view top-rated stocks. What is Alector's stock price forecast for 2022? 6 analysts have issued twelve-month price targets for Alector's stock. Their ALEC stock forecasts range from $6.00 to $57.00. On average, they anticipate Alector's share price to reach $29.86 in the next year. This suggests a possible upside of 178.3% from the stock's current price. View analysts' price targets for Alector or view top-rated stocks among Wall Street analysts. How has Alector's stock performed in 2022? Alector's stock was trading at $20.65 at the beginning of the year. Since then, ALEC stock has decreased by 48.0% and is now trading at $10.73. View the best growth stocks for 2022 here. When is Alector's next earnings date? Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Alector. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) released its earnings results on Thursday, November, 4th. The company reported $1.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $1.95. The business earned $182.41 million during the quarter, compared to the consensus estimate of $407.41 million. Alector had a negative trailing twelve-month return on equity of 10.57% and a negative net margin of 12.65%. View Alector's earnings history. Who are Alector's key executives? Alector's management team includes the following people: Dr. Tillman Ulf Gerngross Ph.D., Co-Founder & Chairman (Age 58, Pay $60k)Dr. Arnon Rosenthal Ph.D., Co-Founder, CEO & Director (Age 66, Pay $972.75k)Dr. Sara Kenkare-Mitra Ph.D., Pres and Head of R&D (Age 54, Pay $552.78k)Mr. Calvin Yu, VP of Fin. (Age 46, Pay $519.69k) (LinkedIn Profile)Dr. Robert S. King, Chief Devel. Officer (Age 59, Pay $658.84k) (LinkedIn Profile)Dr. Marc Grasso M.D., Chief Financial Officer (Age 48)Michelle Corral, VP of Communications & Investor RelationsMs. Danielle Pasqualone J.D., Ph.D., Interim Gen. CounselErica Jefferson, VP of Communications & Public AffairsMs. Clare Hunt M.B.A., Head of People What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Alector's key competitors? Some companies that are related to Alector include Abcam (ABCM), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Bavarian Nordic A/S (BVNRY), Twist Bioscience (TWST), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Allogene Therapeutics (ALLO), Krystal Biotech (KRYS), ImmunityBio (IBRX), Iovance Biotherapeutics (IOVA), Exscientia (EXAI), Immunocore (IMCR) and Recursion Pharmaceuticals (RXRX). View all of ALEC's competitors. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO). When did Alector IPO? (ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. What is Alector's stock symbol? Alector trades on the NASDAQ under the ticker symbol "ALEC." Who are Alector's major shareholders? Alector's stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (7.12%), Vanguard Group Inc. (6.53%), BlackRock Inc. (6.44%), State Street Corp (4.60%), JPMorgan Chase & Co. (2.95%) and Renaissance Technologies LLC (0.85%). Company insiders that own Alector stock include Arnon Rosenthal, Calvin Yu, David M Wehner, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Sabah Oney, Shehnaaz Suliman and Terrance Mcguire. View institutional ownership trends for Alector. Which major investors are selling Alector stock? ALEC stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Goldman Sachs Group Inc., Citigroup Inc., Vanguard Group Inc., Bank of America Corp DE, JPMorgan Chase & Co., PDT Partners LLC, and Pier Capital LLC. Company insiders that have sold Alector company stock in the last two years include Arnon Rosenthal, Calvin Yu, Richard H Scheller, Robert King, Robert Paul, and Shehnaaz Suliman. View insider buying and selling activity for Alector or view top insider-selling stocks. Which major investors are buying Alector stock? ALEC stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Nordea Investment Management AB, Massachusetts Financial Services Co. MA, Nantahala Capital Management LLC, and Raymond James & Associates. View insider buying and selling activity for Alector or or view top insider-buying stocks. How do I buy shares of Alector? Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alector's stock price today? One share of ALEC stock can currently be purchased for approximately $10.73. How much money does Alector make? Alector (NASDAQ:ALEC) has a market capitalization of $894.10 million and generates $207.09 million in revenue each year. The company earns $-36.33 million in net income (profit) each year or ($0.420010) on an earnings per share basis. How many employees does Alector have? Alector employs 208 workers across the globe. How can I contact Alector? Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for Alector is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at [email protected]. This page (NASDAQ:ALEC) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here